However, anti‐TGF‐β therapy has not shown efficacy in patients with diabetic kidney disease or focal segmental glomerulosclerosis (FSGS) (Trachtman et al., 2011; Vincenti et al., 2017; Voelker et al., 2017). The gene discussed is TGFB1; the disease is focal segmental glomerulosclerosis.